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Abstract
Background Detection of unknown risks with marketed
medicines is key to securing the optimal care of individual
patients and to reducing the societal burden from adverse
drug reactions. Large collections of individual case reports
remain the primary source of information and require
effective analytics to guide clinical assessors towards likely
drug safety signals. Disproportionality analysis is based
solely on aggregate numbers of reports and naively disre-
gards report quality and content. However, these latter
features are the very fundament of the ensuing clinical
assessment.
Objective Our objective was to develop and evaluate a
data-driven screening algorithm for emerging drug safety
signals that accounts for report quality and content.
Methods vigiRank is a predictive model for emerging
safety signals, here implemented with shrinkage logistic
regression to identify predictive variables and estimate
their respective contributions. The variables considered for
inclusion capture different aspects of strength of evidence,
including quality and clinical content of individual reports,
as well as trends in time and geographic spread. A refer-
ence set of 264 positive controls (historical safety signals
from 2003 to 2007) and 5,280 negative controls (pairs of
drugs and adverse events not listed in the Summary of
Product Characteristics of that drug in 2012) was used for
model fitting and evaluation; the latter used fivefold cross-
validation to protect against over-fitting. All analyses were
performed on a reconstructed version of VigiBase as of
31 December 2004, at around which time most safety
signals in our reference set were emerging.
Results The following aspects of strength of evidence
were selected for inclusion into vigiRank: the numbers of
informative and recent reports, respectively; dispropor-
Key Points
Today, automated screening of large collections of
individual case reports to identify possible drug
safety issues often relies on disproportionality
analysis, which is based solely on aggregate numbers
of reports, disregarding report quality and content
This study identifies the following variables as strong
predictors of emerging drug safety issues: the
number of informative reports, recent reports, and
reports with free-text descriptions; disproportional
reporting; and geographic spread. Simultaneously
accounting for these aspects of strength of evidence
significantly improves the accuracy of automated
screening of individual case reports compared with
disproportionality analysis alone
Utilizing the identified predictive model can be
expected to reduce the number of false alerts and
uncover drug safety issues that would otherwise go
undetected
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tional reporting; the number of reports with free-text
descriptions of the case; and the geographic spread of
reporting. vigiRank offered a statistically significant
improvement in area under the receiver operating charac-
teristics curve (AUC) over screening based on the Infor-
mation Component (IC) and raw numbers of reports,
respectively (0.775 vs. 0.736 and 0.707, cross-validated).
Conclusions Accounting for multiple aspects of strength
of evidence has clear conceptual and empirical advantages
over disproportionality analysis. vigiRank is a first-of-its-
kind predictive model to factor in report quality and con-
tent in first-pass screening to better meet tomorrow’s post-
marketing drug safety surveillance needs.
1 Introduction
Medicines enable patients to lead better lives and are
fundamental to modern healthcare. However, any effective
medicine comes with a risk of adverse effects, many of
which are serious enough to end or dramatically change the
lives of individual patients. Taken together, adverse drug
reactions (ADRs) impose an enormous burden on society,
causing hundreds of thousands of deaths annually [1, 2] at a
cost of several billion $US [3].
Pre-marketing clinical trials include too few patients
from groups that are too homogeneous to capture a drug’s
full spectrum of possible adverse effects, which makes
extensive post-marketing surveillance a necessity [4]. The
detection of a previously unknown safety issue can have
great impact on the overall benefit–risk balance of a drug,
as evidenced for example by the market withdrawal of
rofecoxib upon the detection of its increased myocardial
infarction risk.
Individual case reports of suspected harm from medi-
cines remain the primary basis to detect unexpected risks of
medicines [5, 6]. Their most important strength is that they
draw on the astute observations of patients and health
professionals to capture information specifically for the
purpose of causality assessment [7]. Further, they cover all
types of medicines and all patient groups in a single sys-
tem. Their major limitations include that far from all sus-
pected ADRs are identified as such, with fewer still being
reported to the authorities, and that many reports lack the
necessary detail to support solid causality assessment. A
number of broad research initiatives currently explore the
use of longitudinal health data for safety signal detection,
and the results suggest that these may complement but not
replace individual case reports for this purpose [8].
A major practical issue in the analysis of individual case
reports to uncover possible new drug risks is their sheer
numerosity. For many concerned organizations, both the
number of submitted reports in itself and the number of
associated drug–ADR combinations are too large for
exhaustive manual review. This necessitates the use of
triages to guide clinical assessment [9–11]. Generally, such
triages can consider three main criteria: strength of evi-
dence, novelty, and medical impact [12]. Since the 1990s,
computerized evaluation of strength of evidence has relied
largely on so-called disproportionality analysis [13–15].
Reflecting its practical value, disproportionality analysis
has evolved from a specialist to a mainstream activity over
the past 15 years [5, 16]. Nevertheless, it provides a very
basic analysis that only accounts for statistical associations
in the co-reporting of drugs and suspected ADRs. It is
entirely based on aggregate numbers of reports and naively
disregards the strength of individual reports. More recently,
multivariate methods have been proposed that account for
co-reported medicines and the indication for treatment [17–
20]. These methods should yield strength-of-association
measures less liable to confounding, although their prac-
tical value for pharmacovigilance is yet to be definitively
demonstrated [21]. In any case, even the multivariate
methods do not consider other information on a given
report beyond its listed drug(s) and ADR(s), and occa-
sionally the indication for treatment. Automated screening
based on deviating patterns of reported time to onset [22] is
conceptually different, but still focuses on a single aspect
of strength of evidence.
This is contrasted by clinical assessment of potential
safety signals, which attempts to manually account for all
relevant aspects [11, 12]. In particular, the quality and
content of individual reports is of fundamental importance
[23]. Consequently, we aim in this paper to combine the
benefits of automation with the breadth of aspects used in
clinical assessment. Specifically, the aim of this paper is to
derive a predictive model for emerging signals of suspected
ADRs from large collections of individual case reports,
accounting for a broad variety of aspects of strength of
evidence, ranging from disproportionality analysis and case
series diversity to individual report quality and content.
This algorithm, denoted vigiRank, is inspired by similar
work for adverse drug interaction surveillance [24].
2 Methods
vigiRank is a predictive model for emerging safety signals,
here implemented with shrinkage logistic regression to
identify predictive variables and estimate their respective
contributions.
2.1 Variables Considered for Inclusion into vigiRank
The variables considered for inclusion into vigiRank cap-
ture inherently different aspects of a reporting pattern that
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might strengthen our suspicion of a true causal association
between the drug and the suspected ADR. This includes
variables that measure the quality and clinical content of
individual reports, as well as more quantitative aspects of a
reporting pattern such as trends in time and geographic
spread. Each considered variable is defined at the level of a
drug–ADR pair and is based on the reporting pattern of that
pair in a specific collection of individual case reports.
Table 1 provides an overview of all proposed variables, with
descriptions and motivations. The final selection of vari-
ables to be empirically evaluated was made by the co-
authors through consensus. Candidate variables were ini-
tially identified through consultation with experienced
pharmacovigilance professionals with clinical (four), phar-
maceutical (five), and statistical (one) expertise. Below, two
non-trivial variables are described in greater detail.
2.1.1 Informative Reports
The ‘informative reports’ variable measures the number of
reports with a vigiGrade completeness score of 0.90 or
more [25]. This score is 1 for a report with full information
on the type of report, type of notifier, time to onset, country
of origin, patient age and sex, indication for treatment,
dosage, outcome, and free text description. It then
decreases with a pre-specified multiplicative factor for each
of these fields that is undocumented. A report with a
vigiGrade completeness score of 0.90 or more may lack
information on only one of the following information
items: type of report, type of notifier, outcome, or free text
description; all other items described above must be
documented.
2.1.2 Disproportional Reporting
The ‘disproportional reporting’ variable is a binary indi-
cator of whether the combination is disproportionally
reported, either on the full dataset or a subset thereof. In
this study, disproportionality is measured using the Infor-
mation Component (IC), a disproportionality measure
based on shrinkage observed-to-expected ratios [13, 26].
The IC is computed as:
IC ¼ log2
O þ 0:5
E þ 0:5 ð1Þ
where O and E are the observed and expected numbers,
respectively, of reports on the drug–ADR pair. E is given
by (NA 9 ND)/N, where NA is the total number of reports
on the ADR; ND is the total number of reports on the drug;
and N is the total number of reports. Credibility intervals
for the IC are obtained via the Gamma distribution [26],
and ICa denotes the a percentile of the posterior distribu-
tion for the IC.
Here, a drug–ADR pair is considered disproportionally
reported when one or more of the following criteria are
fulfilled: IC025 [ 0 on the full data; IC005 [ 0 on the full
data when adjusting for age group, notifier, calendar year,
or country; IC0005 [ 0 in a stratum of the data based on age
group or notifier; IC005 [ 0 in two strata for the same
covariate based on age group, notifier, or country; or
IC0005 [ 0 for the full data when excluding one stratum
based on age group, notifier, country, or calendar year.
Here, IC025, IC005, and IC0005 denote the lower limits of 95,
99, and 99.9 % credibility intervals for the IC, respectively.
Stratifications and interval widths have been selected to
protect against spurious associations from multiple com-
parisons according to Hopstadius and Nore´n [27].
2.2 Reference Set
To be able to identify reporting characteristics of emerging
safety signals, a reference set of positive and negative
controls was created. A total of 532 historical European
Medicine Agency (EMA) safety signals from September
2003 to March 2007 for 267 European centrally authorized
products (CAPs) were considered as potential positive
controls of our reference set [28]. Each had an index date
reflecting when the EMA first became aware that it
required investigation.
Data on the proposed variables were extracted from the
World Health Organization (WHO) global individual case
safety report database, VigiBase [29], for all potential
controls. As of March 2014, VigiBase included more than
8.5 million reports from 118 countries. Here, vaccine
reports and suspected duplicate reports were excluded [30].
Since we focused on emerging safety issues, a VigiBase
reconstruction as of 31 December 2004 was used; this date
is the end of the quarter in which the median of the index
dates fell. No attempt was made to recreate the actual
composition of VigiBase at that time. Instead, reports were
time-stamped based on the date of the suspected ADR, or
an approximation thereof.
After updating to the Medical Dictionary for Regulatory
Activities (MedDRA), version 14.1, matching substance
names to the preferred base level of WHO Drug Dictionary
EnhancedTM, excluding vaccines, and requiring reports
from at least two countries, 264 positive controls from 65
CAPs remained. As intended, by the rollback date of 31
December 2004, a vast majority of these were emerging
rather than established safety signals: by this date only 30
of 264 (11 %) had led to regulatory action by the EMA,
and for 118 (45 %) this date preceded the point in time
when EMA first became aware of the potential safety
signal. The reference set also included randomly selected
negative controls, at a 20:1 ratio with the positive controls.
Negative controls were pairs of the initial 267 CAPs and
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MedDRA preferred terms for which no other preferred
term from the same MedDRA high-level term was
included in Section 4.8 of the 2012 European summary of
product characteristics (SPC) of that drug. MedDRA-
encoded European SPCs were obtained from the PRO-
TECT database, available at http://www.imi-protect.eu/
methodsRep.shtml. All 5,544 drug–ADR pairs of the ref-
erence set were required to have reports from at least two
countries in VigiBase by 31 December 2004.
2.3 Fitting the vigiRank Model
vigiRank was derived by fitting a shrinkage logistic
regression model to the reference set, using all variables
described in Table 1 as candidate explanatory variables.
Shrinkage regression was employed on account of its ability
to avoid over-fitting to sampling variability of the training
data [31]. The specific type of shrinkage called ‘lasso’ was
used, as it simultaneously selects variables and estimates
their relative contributions to the predictive model; that is, it
sets the weights of most explanatory variables to zero [32].
2.3.1 Variable Transformation
Prior to regression modelling, all numerical variables, i.e.
all except ‘disproportional reporting’ and ‘time trend’ (see
Table 1), were subjected to mathematical transformation
(see Fig. 1). The main aim of this was to impose a law of
diminishing returns, gradually decreasing the impact from
additional reports of a given kind, e.g. with positive de-
challenge. This is important in order not to exclusively
rank very large case series at the top.
As seen in Fig. 1, the transformations all have an
identical shape but differ in the first number of reports (or
countries) to be rewarded. The shape of the transformation
was selected prior to modelling and not altered in light of
its results. The threshold for each covariate was determined
empirically as the lowest number that applied to fewer than
20 % of a random sample of negative controls, separate to
those used to subsequently fit and evaluate the model. For
example, 30 % of negative controls in the random sample
have two or more dechallenge reports, whereas only 19 %
have three or more. Hence, the threshold for ‘dechallenge’
was set to three reports. Whereas the transform for ‘recent
reporting’ follows the same shape, it yields values between
-1 and 0 instead of between 0 and 1. It therefore penalizes
drug–ADR pairs with few recent reports rather than
rewards pairs with many recent reports.
2.3.2 Regression Modelling
All regression analysis relied on the specific implemen-
tation of lasso logistic regression provided by Friedman
et al. [33]. Prior to model fitting, all transformed vari-
ables were standardized to unit variance. However, all
presented coefficients apply to the transformed variables
on their original scale, as shown in Fig. 1. For details on
the lasso logistic regression model, please see the
Appendix.
Shrinkage regression requires selecting a degree of
shrinkage that determines the model size. In this study, all
considered variables were designed to be positive predic-
tors, i.e. to independently add to the likelihood that a drug–
ADR pair represents a safety signal, if at all included.
Therefore, any estimated negative coefficient was taken to
suggest over-fitting, and consequently the selected shrink-














































Fig. 1 Mathematical transforms used for numerical variables to
gradually decrease the reward from additional units (i.e. reports or
reporting countries). The respective points at which the transforms
begin to increase were determined empirically based on the variables’
frequency among the negative controls
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2.4 Performance Evaluation
vigiRank utilizes a logistic regression model, and produces
a score for each drug–ADR pair reflecting the probability
that it represents an emerging safety signal (for details, see
the Appendix). This score has no natural threshold, for
which reason performance was evaluated in terms of
receiver operating characteristic (ROC) curves, which
display sensitivity and specificity at varying thresholds.
The area under the ROC curve (AUC) was used as
aggregate measure of predictive performance. AUC is a
standard summary metric for comparisons over all possible
thresholds in ROC analyses.
To study its performance relative to standard dispro-
portionality analysis, vigiRank was compared with the IC
(see Sect. 2.1.2). Following routine use, the IC was
employed without adjustments or stratifications, and IC025
was used to decide which drug–ADR pairs to highlight at a
given threshold. Comparison was also made against a crude
screening strategy based on a drug–ADR pair’s raw num-
ber of reports, representing the first paradigm of quantita-
tive analysis in pharmacovigilance. The performance of all
three methods was evaluated with the reference set of
historic EMA safety signals as benchmark.
2.5 Cross-Validation
Because the same data were used to develop and evaluate
vigiRank, there might be a risk of over-estimating its
predictive performance. To manage this risk, regression
modelling and performance evaluation was repeated
within fivefold cross-validation. First, the entire reference
set was randomly divided into five equally sized folds.
Then, withholding one fold at a time, a lasso logistic
model was fitted as described for the entire reference set
above; notably, the degree of shrinkage was determined
anew in each of the five iterations. For each of the five
models, the withheld fold was used as benchmark in the
evaluation.
Accurate ascertainment of predictive performance was
not the only purpose of this cross-validation scheme.
Investigation of vigiRank’s robustness was enabled by
comparing the model fitted from the entire reference set
with the five models obtained in cross-validation.
3 Results
3.1 vigiRank: A Predictive Model for Emerging Safety
Signals
The variables selected by lasso logistic regression for
inclusion into vigiRank are shown in Fig. 2a: ‘informative
reports’, ‘recent reporting’, ‘disproportional reporting’,
‘narrative’, and ‘geographic spread’. Further, Fig. 2b dis-
plays the models obtained in cross-validation. Robustness
does not appear to be an issue: the above five variables
were selected in each of the five cross-validation iterations,
with little variability in the magnitude of the estimated
coefficients. The only other variable selected was ‘de-
challenge’, which was included with small coefficients in
two iterations.
Figure 3 provides a fictional example to schematically
describe how vigiRank works in practice.
3.2 Overall Predictive Performance
The results from the performance evaluation based on the
entire reference set are shown in Fig. 4a. The ROC curve
corresponding to vigiRank is consistently above the other
two, indicating that, at any given specificity, vigiRank will
yield higher sensitivity than both IC025 and raw numbers of
reports; and conversely, at any given sensitivity, vigiRank
will yield higher specificity. This obviously includes the
region around the natural threshold for IC025, zero. Fur-
thermore, vigiRank offered a statistically significant
improvement in AUC over IC025 (0.775 vs. 0.736, cross-
validated), which is greater in magnitude than the differ-
ence between IC025 and raw numbers of reports (0.736 vs.
0.707). For reference, when considered in isolation, the
predictive performance of disproportionality analysis
extended for subgroup discovery as described in Sect.
2.1.2, was 0.743.
For vigiRank, the mean AUC value across the five cross-
validation iterations differed only marginally compared
with that obtained with the entire reference set, and there
was no difference at all for the other two methods (see
Fig. 4b). In all five iterations, vigiRank performed best and
IC025 second best.
3.3 Examples of Emerging Signals Highlighted
or Overlooked by vigiRank
In line with vigiRank’s overall better performance, some
emerging signals missed by IC025 were highly ranked by
vigiRank. Others yet obtained lower ranks, reflecting
vigiRank’s less-than-perfect performance as a first-pass
filter. Table 2 shows the three positive controls with neg-
ative IC025 that obtained highest ranks and the three posi-
tive controls that obtained overall lowest ranks, according
to vigiRank.
The example olanzapine–bradycardia (see Table 2)
illustrates vigiRank’s ability to consider local stratum-
specific or adjusted effects. This allows it to highlight
emerging safety signals not detected by standard dispro-
portionality analysis: while the global IC025 is negative,
622 O. Caster et al.
there is disproportional reporting (IC005 [ 0) for the age
groups 12–17 years and 18–44 years.
Even in the complete absence of disproportional
reporting, vigiRank can utilize other reporting patterns to
yield high ranks, as for the two clopidogrel signals in
Table 2, which are driven by the other four included pre-
dictors. Each of these three signals have additional support
from variables not included in this vigiRank implementa-
tion, such as ‘dechallenge’, ‘rechallenge’, ‘probable/certain
causality’, and ‘solely reported’.
The three low-ranked positive controls naturally have
minimal reporting on the variables included in vigiRank.
Two of them, raloxifene–arterial thrombosis and pramip-
exole–hyperkinesia (see Table 2), have very little empirical
support overall. However, for nelfinavir–erythema multi-
forme, the underlying data—in particular the five positive
dechallenge reactions—might have been able to support a
positive statement on causality in a subsequent clinical
assessment.
4 Discussion
Adverse effects from medicines are a major impediment to
beneficial pharmacological therapy: they cause mortality
and morbidity, and trigger patients to stop otherwise
effective treatment. With many risks unknown at the time
of marketing, detecting those risks as timely and accurately
as possible is of utmost importance. One of the greatest
opportunities towards this end is to adapt first-pass
screening to account for the varying strength of individual
case reports. As in clinical assessment, computational
methods can then look beyond aggregate numbers and
prioritize case series more likely to contain convincing
reports and reporting patterns. Our results indicate that this
may improve performance as much as did the previous
paradigm shift from screening based on raw numbers of
reports to disproportionality analysis.
Our new screening algorithm, vigiRank, considers the
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Fig. 2 a Estimated coefficients by lasso logistic regression for all considered variables. The top five variables with non-zero coefficients define
our new screening algorithm, vigiRank. The model intercept was -3.45. b All non-zero coefficients estimated by lasso logistic regression for any
variable, either based on all data (as in a) or when excluding a fold during fivefold cross-validation. Positive and negative controls were randomly
assigned to one of five folds, so that each fold contains 20 % of the entire reference dataset
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timing and geographic spread of the case series, and the
unexpectedness of the reporting pattern. Our version of
disproportionality analysis goes further than what is cus-
tomary today: it also identifies local associations unique to,
for example, geographic regions or age groups [27].
Markers of presumed clinical relevance of individual
reports were considered as potential predictors but not
selected for the final model. These include explicit
assessment of causality by the reporter or national center,
records of dechallenge interventions where the adverse
event had resolved upon end of treatment, and records of
rechallenge interventions where the adverse event had
reappeared upon re-exposure to the drug. The latter was
identified by experts as an important aspect of strength of
evidence for pharmacovigilance triages [12]. However, an
important difference is that their ascertainment of positive
rechallenges is based on manual review, whereas we rely
on already encoded information in the database, which may
not be perfectly trustworthy. As regards strong causality
assessment, this may be unlikely for adverse events not yet
known to be associated with the drug, as considered here.
Conversely, the predictive ability of informative reports
and case narratives was not expected. These predictors
measure the amount of information, but not whether it
supports a causal association. As a case in point, the
vigiGrade completeness measure looks at whether there is
information on time to onset, but not whether the reported
time to onset is suggestive of a causal association. Of
course, the amount of information on a report may corre-
late with the strength of suspicion and perceived impor-
tance of the case. Viewed differently, case series with no
informative reports or case narratives may be less likely to
reflect true adverse effects.
An advantage of vigiRank over rule-based alternatives is
that it imposes no hard requirement on any individual
predictor. Lack of informative reports can be compensated
for, for example, by disproportional reporting, narratives,
and recent reporting; and fewer than expected reports
overall can be compensated for, for example, by informa-
tive reports and geographic spread. The previously
described triage for adverse drug interaction surveillance in
VigiBase [24] conforms to the vigiRank framework. One
important new development in the implementation pre-
sented here compared with that for interactions is the
principle of diminishing returns for additional reports ful-
filling the same criteria (recent, informative, or with nar-
ratives), and for additional countries with disproportional
reporting rates. This is important since emerging safety
signals must be detected early, and it would be unwise to
place undue focus on series of very large numbers of
reports. By design, vigiRank is less likely than basic dis-
proportionality analysis to highlight report series with as
few as three reports. Three reports has been taken as a rule
of thumb of minimal support for a safety signal, but the
original publication from which this derives actually calls
for three strongly supportive cases, which is quite different
[23].
We developed and evaluated a first-pass screening
algorithm for VigiBase, which is the world’s largest data-
base of its kind. Its implementation in a different context
would require the predictor variables to be adapted. For
example, an informative report may be defined as one that
carries information in a minimum number of record fields
important for the database of interest, and geographic
spread in a national dataset could be measured in terms of
states or regions. As for unexpectedness, a different mea-
sure of disproportionality and threshold can replace our
proposed combination of global and local IC analysis. We
believe that vigiRank would also bring value over basic
disproportionality analysis in other databases. Ideally, the
weights of the model should be optimized to the new set-
ting. If so, the transformations for predictor variables based
on numbers of reports and geographical units could be
adapted to peak earlier for smaller databases. With less
resource, one may consider recycling the weights presented
here. In either case, empirical evaluation of performance
for the dataset of interest is crucial.
Fig. 3 Outline of how vigiRank applies to a set of eight reports on a
fictional drug–adverse drug reaction pair. The first part shows a
conceptual summary of each report. As an example, the top left report
is a report from Switzerland that includes a case narrative, attains a
vigiGrade completeness score of 1.0, and was received in 1995. The
second part shows the raw data for each of the predictors (three
informative reports, four recent reports, disproportionality = TRUE,
three reports with case narratives, and four countries of origin with
positive Information Component). The third part displays the
corresponding transformed values that are multiplied with their
corresponding estimated coefficients. The fourth part sums the
independent contributions from all variables with the intercept
(-3.45) to produce the overall score of -1.45 on logit scale, which
corresponds to a 19 % probability. Either the score or the probability
could be used for ranking purposes. Note: here the year 2014 is used
as a reference point to determine whether or not a report is recent
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The main limitation of our study is the lack of an
external benchmark to evaluate predictive performance.
Cross-validation indicates that vigiRank is not over-fitted
to sampling variability of the reference dataset: the mean
cross-validated AUC is marginally below that for the
reference dataset as a whole, the selected predictors and
their coefficients are remarkably consistent over the five
cross-validation iterations, and vigiRank consistently
outperforms IC025 over all iterations. However, vigiRank
could be over-fitted to the nature of the reference set in
question. The strengths of the reference set from Alvarez
et al. [28] include its focus on risks identified post-mar-
keting, and the possibility to backdate the analysis to
before their discovery. However, it is restricted to Euro-
pean safety signals in the early 2000s, and these could
differ systematically from safety signals in different
regions and time periods. Our positive controls do have
lower proportions of North American reports than does
VigiBase overall, but beyond that European reports are
not over-represented compared with other continents. This
is important since the proportion of informative reports in
VigiBase is higher from Europe than from other regions
[25].
This implementation of vigiRank is not a proposed final
solution, but a first step towards a new paradigm that will
allow more effective automated screening of individual
case reports. It has clear advantages over basic dispropor-
tionality analysis, conceptually as well as empirically, and
should be adopted for routine use. However, further
enhancements must follow. Other predictive models should
be considered, including ensemble methods, which have
proven powerful in other settings [34]. Other benchmarks
should be utilized to ensure generalizability. Some of the
predictors developed here, but not selected, should be
considered further, particularly ‘dechallenge’, which was
included in two of the cross-validation models. Additional
‘negative’ predictors aimed at eliminating false positives,
similar to (lack of) recent reports in the current version of
vigiRank is an interesting possibility. As an example,
lack—or a very low proportion—of reports without co-
reported drugs could potentially eliminate false positives.
We should also consider novel predictors based on recent
innovations such as the measure of unexpected reported
time to onset proposed by Van Holle et al. [22]. Combi-
nation with multivariate methods to account for co-repor-
ted drugs and indications for treatment at the report level
through regression [17, 19, 20] or propensity score models
[18] is particularly interesting, since these aspects are not
captured by any of the predictors in the current model, and
have yielded similar increases in performance [18, 20]. As
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b
Fig. 4 a Receiver operating characteristic curves for our new screening algorithm, vigiRank, standard disproportionality analysis (IC025), and
raw numbers of reports, relative to the benchmark based on historic European Medicines Agency safety signals. The difference between
vigiRank and IC025 is statistically significant (p \ 0.001 using DeLong’s test [36]). The circle corresponds to the standard threshold for IC025, 0,
and the 45 line corresponds to random guessing. b Area under the curve (AUC) values for the three methods from the evaluation on all data as
well as from the individual iterations of the cross-validation. The error bars indicate 95 % confidence intervals. The mean values over the cross-
validation folds are 0.775, 0.736, and 0.707 for vigiRank, IC025, and raw numbers of reports, respectively. IC information component, IC025 is the
lower limit of the two-sided 95 % credibility interval for the IC disproportionality measure
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5 Conclusions
Accounting for multiple aspects of strength of evidence has
clear conceptual and empirical advantages over dispro-
portionality analysis. vigiRank is a first-of-its-kind pre-
dictive model to factor in report quality and content in first-
pass screening to better meet tomorrow’s post-marketing
drug safety surveillance needs.
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Appendix: vigiRank as a lasso logistic regression model
To appreciate the lasso logistic regression model chosen
for the purpose of deriving the new screening algorithm




1  PðyjxÞ ¼ b0 þ b1x1 þ    þ bpxp ð2Þ
where p denotes the number of candidate variables, xj
denotes the jth predictor variable, and y the outcome (in our
case emerging safety signal or not). The bj’s can be viewed
as log odds ratios adjusted for the impact of the other
covariates [35].
As shown in Fig. 1, all variables except those that are




1  PðyjxÞ ¼ b0 þ b1f1ðx1Þ þ    þ bpfpðxpÞ ð3Þ
where fj is the transformation applied to the jth variable.
(Trivially, for the binary variables f(x) = x.)
Now, lasso logistic regression extends standard











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  t ð4Þ
There are multiple ways to estimate the bj coefficients
under this constraint. In this study, the algorithm provided
by Friedman et al. [33] was used, which allows the
coefficients to be estimated for the whole path of possible
values for the tuning parameter t in Eq. 4. This parameter
determines the amount of shrinkage and therefore the size
of the model; see Sect. 2.3.2 for a description of how the
model size of vigiRank was selected.
Since vigiRank is a logistic regression model, once its
coefficients have been estimated as described above, it can
be used to make predictions for arbitrary drug–ADR pairs
regarding their likelihood of representing emerging safety
signals. Solving Eq. 3 for P(y|x) yields:
PðyjxÞ ¼ expðb0 þ b1f1ðx1Þ þ    þ bpfpðxpÞÞ
1 þ expðb0 þ b1f1ðx1Þ þ    þ bpfpðxpÞÞ
ð5Þ
Figure 3 provides a detailed description of how Eq. 5 is
applied to a set of eight reports for a fictional drug–ADR
pair, using the actual transformations fj and coefficients bj
of the final vigiRank model. In practice, there are a large
number of drug–ADR pairs, which are ranked according to
their respective predicted P(y|x).
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